Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 16/20 | 0.83 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.65 |
| ▸ | MEF2D | Q14814 | 4/20 | 0.65 |
| ▸ | EP300 | Q09472 | 2/20 | 0.65 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.58 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.58 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.58 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.58 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.58 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.58 |
| ▸ | KDM1A | O60341 | 1/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8349389 | 1.00 | HDAC1 (0.83) | HDAC1HDAC4MEF2DEP300HDAC3 | |
| SCHEMBL3565983 | 1.00 | HDAC1 (0.83) | HDAC1HDAC4MEF2DEP300HDAC3 | |
| SCHEMBL1065916 | 0.91 | HDAC1 (1.00) | HDAC1HDAC4MEF2DEP300HDAC3 | |
| SCHEMBL8348764 | 0.91 | HDAC1 (1.00) | HDAC1HDAC4MEF2DEP300HDAC3 | |
| SCHEMBL1065917 | 0.91 | HDAC1 (1.00) | HDAC1HDAC4MEF2DEP300HDAC3 | |
| SCHEMBL12963524 | 0.90 | HDAC1 (0.85) | HDAC1HDAC4MEF2DEP300HDAC3 | |
| SCHEMBL1063547 | 0.89 | HDAC1 (0.83) | HDAC1HDAC4MEF2DEP300HDAC3 | |
| SCHEMBL1065907 | 0.89 | HDAC1 (0.83) | HDAC1HDAC4MEF2DEP300HDAC3 | |
| SCHEMBL8348922 | 0.89 | HDAC1 (0.87) | HDAC1HDAC4MEF2DEP300HDAC3 | |
| SCHEMBL8349170 | 0.89 | HDAC1 (0.83) | HDAC1HDAC4MEF2DEP300HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868204-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2011-01-11 | — | — | US | disclosed |
| US-7838520-B2 | Inhibitors of histone deacetylase | METHYLGENE, INC. (CA) | 2010-11-23 | — | — | US | disclosed |
| US-7595343-B2 | Inhibitors of histone deacetylase | METHYLGENE, INC. (CA) | 2009-09-29 | — | — | US | disclosed |
| US-20060058298-A1 | Inhibitors of histone deacetylase | METHYLGENE, INC. | 2006-03-16 | — | — | US | disclosed |
| US-20050288282-A1 | Inhibitors of histone deacetylase | METHYLGENE, INC. | 2005-12-29 | — | — | US | disclosed |
| US-6897220-B2 | Inhibitors of histone deacetylase | METHYLGENE, INC. (CA) | 2005-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288282-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC5, HDAC3 | HDAC1 1/4885HDAC4 8/4885MEF2D 1367/4885 |
| US-20060058298-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC5, HDAC3 | HDAC1 1/4885HDAC4 8/4885MEF2D 1367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.